Search research articles
Contact Us
Filters
Showing results (151-160 of 186) with videos related to
Page
of 19
Sort By:
Oncotarget
|
November 22, 2017
Overcoming resistance to single-agent therapy for oncogenic <i>BRAF</i> gene fusions <i>via</i> combinatorial targeting of MAPK and PI3K/mTOR signaling pathways
Payal Jain, Amanda Silva, Harry J Han, et al.
The Lancet. Oncology
|
December 9, 2019
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial
Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, et al.
JCO Precision Oncology
|
September 19, 2024
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I)
Margaret E Macy, Rajen Mody, Joel M Reid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2022
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial
Olive S Eckstein, Carl E Allen, P Mickey Williams, et al.
Pediatric Blood & Cancer
|
May 2, 2025
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors
Filemon S Dela Cruz, Elizabeth Fox, Steven G DuBois, et al.
JCO Precision Oncology
|
June 27, 2024
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
Kieuhoa T Vo, Amit J Sabnis, P Mickey Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2022
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
D Williams Parsons, Katherine A Janeway, David R Patton, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 15, 2022
ACCELERATE - Five years accelerating cancer drug development for children and adolescents
Andrew D J Pearson, Susan L Weiner, Peter C Adamson, et al.
G3 (Bethesda, Md.)
|
December 7, 2023
Simplified homology-assisted CRISPR for gene editing in Drosophila
Anne E Rankin, Elizabeth Fox, Townley Chisholm, et al.
JCO Precision Oncology
|
September 19, 2024
Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D
Theodore W Laetsch, Kathleen Ludwig, P Mickey Williams, et al.
Page
of 19
Search research articles
Search
Showing results (151-160 of 186) with videos related to
Sort By:
Page
of 19
Oncotarget
|
November 22, 2017
Overcoming resistance to single-agent therapy for oncogenic <i>BRAF</i> gene fusions <i>via</i> combinatorial targeting of MAPK and PI3K/mTOR signaling pathways
Payal Jain, Amanda Silva, Harry J Han, et al.
The Lancet. Oncology
|
December 9, 2019
Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial
Birgit Geoerger, Hyoung Jin Kang, Michal Yalon-Oren, et al.
JCO Precision Oncology
|
September 19, 2024
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I)
Margaret E Macy, Rajen Mody, Joel M Reid, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 1, 2022
Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial
Olive S Eckstein, Carl E Allen, P Mickey Williams, et al.
Pediatric Blood & Cancer
|
May 2, 2025
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric and Young Adult Solid Tumors
Filemon S Dela Cruz, Elizabeth Fox, Steven G DuBois, et al.
JCO Precision Oncology
|
June 27, 2024
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
Kieuhoa T Vo, Amit J Sabnis, P Mickey Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 30, 2022
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial
D Williams Parsons, Katherine A Janeway, David R Patton, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 15, 2022
ACCELERATE - Five years accelerating cancer drug development for children and adolescents
Andrew D J Pearson, Susan L Weiner, Peter C Adamson, et al.
G3 (Bethesda, Md.)
|
December 7, 2023
Simplified homology-assisted CRISPR for gene editing in Drosophila
Anne E Rankin, Elizabeth Fox, Townley Chisholm, et al.
JCO Precision Oncology
|
September 19, 2024
Phase II Study of Samotolisib in Children and Young Adults With Tumors Harboring Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Pathway Alterations: Pediatric MATCH APEC1621D
Theodore W Laetsch, Kathleen Ludwig, P Mickey Williams, et al.
Page
of 19